Business
Picard Medical Reports Second Quarter 2025 Financial Results
Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 20
About this update from Picard Medical, Inc.
[{"type":"image","alt":"Picard Medical, Inc.","displaySize":"","headline":null,"caption":"Picard Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":266,"url":"https://media.zenfs.com/en/globenewswire.com/7aed5ca33d8d3f4fa4e291322577bb8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GgCsyHKApDgH7PlfNRrYtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7aed5ca33d8d3f4fa4e291322577bb8f","width":300,"height":266}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong commercial momentum driven by higher product sales – ","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology -","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":174,"olType":false},{"type":"text","content":"TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early September, Picard successfully closed its initial public offering, raising gross proceeds of $19.5 million.","length":449,"tagName":"p"},{"type":"text","content":"“Our second quarter results reflect strong sales growth for the SynCardia total artificial heart,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical. “We achieved over 200% revenue growth year-over-year, strengthened our operating profile, and successfully completed our IPO the proceeds of which provide us with the capital to advance development of our next-generation fully implantable heart and expand access to the SynCardia platform globally.”","length":472,"tagName":"p"},{"type":"text","content":"Second Quarter 2025 Results","length":27,"tagName":"p"},{"type":"text","content":"Revenue for the second quarter of 2025 increased 207% to $2.13 million, compared with $0.69 million in the second quarter of 2024. Growth was driven entirely by higher U.S. product sales. Gross loss narrowed to $0.13 million, a 67% improvement compared with the prior year. Operating loss improved 8% to $3.52 million, versus $3...